Rhenman & Partners Asset Management AB Acquires 1,750 Shares of BioNTech SE (NASDAQ:BNTX)

Rhenman & Partners Asset Management AB boosted its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,750 shares of the company’s stock after acquiring an additional 1,750 shares during the period. Rhenman & Partners Asset Management AB’s holdings in BioNTech were worth $6,011,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of BNTX. Jones Financial Companies Lllp increased its stake in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. raised its stake in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after buying an additional 700 shares during the last quarter. Allianz SE bought a new stake in BioNTech in the fourth quarter worth $90,000. GAMMA Investing LLC grew its stake in shares of BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after acquiring an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech in the fourth quarter worth $137,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $88.05 on Friday. The company has a market cap of $21.13 billion, a P/E ratio of -41.93 and a beta of 1.07. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm’s fifty day moving average is $108.81 and its two-hundred day moving average is $112.88.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the previous year, the firm posted $1.90 earnings per share. The business’s revenue was down 19.5% compared to the same quarter last year. As a group, analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Wells Fargo & Company initiated coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. BMO Capital Markets boosted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Morgan Stanley cut their price target on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Citigroup began coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Finally, HC Wainwright reduced their target price on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a report on Tuesday. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.